The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.
Researchers used genomic, transcriptomic, and virulence data on thousands of Streptococcus pyogenes strains to identify features influencing infections.
At the ICG-13 conference, BGI previewed a high-throughput sequencer, MGISEQ-T7, that will be commercially available in 2019 and have a throughput of up to 20,000 genomes per year.
